Bluejay Diagnostics (BJDX) vs. Its Competitors Head-To-Head Comparison

Bluejay Diagnostics (NASDAQ:BJDXGet Rating) is one of 216 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Bluejay Diagnostics to similar companies based on the strength of its risk, earnings, valuation, analyst recommendations, institutional ownership, dividends and profitability.


This table compares Bluejay Diagnostics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bluejay Diagnostics N/A -52.42% -44.29%
Bluejay Diagnostics Competitors -743.58% -54.90% -19.48%

Valuation & Earnings

This table compares Bluejay Diagnostics and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bluejay Diagnostics N/A -$3.49 million -2.95
Bluejay Diagnostics Competitors $1.14 billion $83.89 million -509.04

Bluejay Diagnostics’ peers have higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and price targets for Bluejay Diagnostics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bluejay Diagnostics 0 0 1 0 3.00
Bluejay Diagnostics Competitors 626 3051 7232 163 2.63

Bluejay Diagnostics currently has a consensus price target of $10.00, indicating a potential upside of 747.46%. As a group, “Surgical & medical instruments” companies have a potential upside of 32.02%. Given Bluejay Diagnostics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Bluejay Diagnostics is more favorable than its peers.

Institutional and Insider Ownership

45.4% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 50.9% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 45.3% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 14.7% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


Bluejay Diagnostics beats its peers on 7 of the 12 factors compared.

Bluejay Diagnostics Company Profile

(Get Rating)

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with's FREE daily email newsletter.